Empagliflozin 10 MG Tablets – Xempia 10 Tablets

Xempia 10 Tablets – Empagliflozin 10 MG Tablets – A next-generation solution for diabetes management with added benefits for heart and kidney health.

Xempia 10 Tablets – Empagliflozin 10 mg Tablets contains Empagliflozin that is a selective SGLT2 inhibitor that lowers blood sugar levels by blocking glucose reabsorption in the kidneys, leading to its increased excretion through urine. Beyond glycemic control, it provides significant cardiovascular and kidney protection, making it a preferred option for managing Type 2 Diabetes Mellitus in patients with associated health risks.
Blood Sugar Regulation: Effectively lowers HbA1c levels in adults with Type 2 Diabetes.
Cardiovascular Protection: Reduces the risk of hospitalization due to heart failure and cardiovascular-related death in diabetic patients.
Renal benefits: Helps slow the progression of kidney disease by reducing glomerular pressure and albuminuria.

Recommended by specialists:
✅Diabetologist: First line treatment for managing Type 2 Diabetes Mellitus
✅Cardiologist: To reduce the risk of heart failure and cardiovascular risk in diabetic patients with existing heart disease.
✅Nephrologist: For patients with diabetic kidney disease, as Empagliflozin helps slow disease progression and reduce albuminuria.

Key benefits of Empagliflozin 10 MG Tablets – Xempia 10 Tablets:
✅Dual Benefit: Provides effective glycemic control in Type 2 Diabetes Mellitus with proven 38% reduction in cardiovascular death in diabetic patients.
✅Weight and Blood Pressure Reduction: Helps promote weight loss and lowers blood pressure as additional benefits of SGLT2 inhibition.
✅Renal Protection: Demonstrates a protective role in kidney function, reducing the progression of diabetic nephropathy.

Indications-
✅ Type 2 Diabetes Mellitus (as mono-therapy or in combination with other anti-diabetic agents)
✅Cardiovascular Risk Reduction in patients with Type 2 Diabetes Mellitus and established cardiovascular disease
✅Prevention of Diabetic Kidney Disease Progression